120 related articles for article (PubMed ID: 9490096)
21. Increased lung cancer risk in patients with interstitial lung disease and elevated CEA and CA125 serum tumour markers.
Dai H; Liu J; Liang L; Ban C; Jiang J; Liu Y; Ye Q; Wang C
Respirology; 2014 Jul; 19(5):707-13. PubMed ID: 24903079
[TBL] [Abstract][Full Text] [Related]
22. Positive reactions for both Cyfra21-1 and CA125 indicate worst prognosis in non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Yamamoto N; Iida T
Anticancer Res; 2003; 23(3C):2869-74. PubMed ID: 12926125
[TBL] [Abstract][Full Text] [Related]
23. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
24. Analysis of the prognostic significance of cytosolic determination of CA 125 tumor-associated antigen, carcinoembryonic antigen and squamous cell carcinoma antigen in patients with nonsmall cell lung carcinoma.
Picardo AL; Diez M; Torres A; Maestro M; Ortega D; Hernando F; Gómez A; Garcia-Asenjo J; Balibrea JL
Cancer; 1996 Mar; 77(6):1066-72. PubMed ID: 8635125
[TBL] [Abstract][Full Text] [Related]
25. Clinical Value of Tumor Markers for Determining Cause of Pleural Effusion.
Gu Y; Zhai K; Shi HZ
Chin Med J (Engl); 2016 Feb; 129(3):253-8. PubMed ID: 26831224
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples.
Thomas DS; Fourkala EO; Apostolidou S; Gunu R; Ryan A; Jacobs I; Menon U; Alderton W; Gentry-Maharaj A; Timms JF
Br J Cancer; 2015 Jul; 113(2):268-74. PubMed ID: 26035703
[TBL] [Abstract][Full Text] [Related]
27. [Clinical Significance of Tumor Marker Detection in Patients
with Advanced Squamous Cell Carcimoma of the Lung].
Liang P; Li J
Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):641-647. PubMed ID: 27760591
[TBL] [Abstract][Full Text] [Related]
28. Cervical carcinoma: a comparison of four potential biochemical tumor markers.
Dodd JK; Henry RJ; Tyler JP; Houghton CR
Gynecol Oncol; 1989 Feb; 32(2):248-52. PubMed ID: 2910788
[TBL] [Abstract][Full Text] [Related]
29. [Changes in serum levels of gynecological tumor markers throughout the period from early gestation to puerperium].
Sugawara T; Tanaka T; Sato H; Hanatani K; Okuyama K; Shinkai N; Sakuragi N; Makinoda S; Fujimoto S
Nihon Sanka Fujinka Gakkai Zasshi; 1991 Feb; 43(2):145-51. PubMed ID: 1707431
[TBL] [Abstract][Full Text] [Related]
30. The clinical values of squamous cell carcinoma antigen and carcinoembryonic antigen in patients with cervical cancer treated with concurrent chemoradiotherapy.
Yoon SM; Shin KH; Kim JY; Seo SS; Park SY; Kang S; Cho KH
Int J Gynecol Cancer; 2007; 17(4):872-8. PubMed ID: 17343571
[TBL] [Abstract][Full Text] [Related]
31. Serum CA242, CA199, CA125, CEA, and TSGF are Biomarkers for the Efficacy and Prognosis of Cryoablation in Pancreatic Cancer Patients.
Chen Y; Gao SG; Chen JM; Wang GP; Wang ZF; Zhou B; Jin CH; Yang YT; Feng XS
Cell Biochem Biophys; 2015 Apr; 71(3):1287-91. PubMed ID: 25486903
[TBL] [Abstract][Full Text] [Related]
32. Utility of squamous cell carcinoma antigen, carcinoembryonic antigen, Cyfra 21-1 and neuron specific enolase in lung cancer diagnosis: a prospective study from China.
Song WA; Liu X; Tian XD; Wang W; Liang CY; Zhang T; Guo JT; Peng YH; Zhou NK
Chin Med J (Engl); 2011 Oct; 124(20):3244-8. PubMed ID: 22088515
[TBL] [Abstract][Full Text] [Related]
33. Value of CEA and SCC-Ag in bronchoalveolar lavage (BAL) and serum of patients with lung carcinoma.
Nikliński J; Chyczewska E; Furman M; Kowal E; Kozłowski M
Neoplasma; 1992; 39(5):283-5. PubMed ID: 1331827
[TBL] [Abstract][Full Text] [Related]
34. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer.
Phocas I; Sarandakou A; Sikiotis K; Rizos D; Kalambokis D; Zourlas PA
Anticancer Res; 1996; 16(6B):3827-31. PubMed ID: 9042265
[TBL] [Abstract][Full Text] [Related]
35. Clinical Evaluation of Tumor Markers for Diagnosis in Patients with Non-small Cell Lung Cancer in China.
Ma L; Xie XW; Wang HY; Ma LY; Wen ZG
Asian Pac J Cancer Prev; 2015; 16(12):4891-4. PubMed ID: 26163610
[TBL] [Abstract][Full Text] [Related]
36. Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer.
Díez M; Torres A; Maestro ML; Ortega MD; Gómez A; Pollán M; Lopez JA; Picardo A; Hernando F; Balibrea JL
Br J Cancer; 1996 May; 73(10):1248-54. PubMed ID: 8630287
[TBL] [Abstract][Full Text] [Related]
37. [Significance of CEA, SCC and Cyfra21-1 serum test in esophageal cancer].
Mao YS; Zhang DC; Zhao XH; Wang LJ; Qi J; Li XX
Zhonghua Zhong Liu Za Zhi; 2003 Sep; 25(5):457-60. PubMed ID: 14575569
[TBL] [Abstract][Full Text] [Related]
38. Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA.
Haglund C
Br J Cancer; 1986 Dec; 54(6):897-901. PubMed ID: 3467786
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of carcinoembryonic antigen, tissue polypeptide antigen, and squamous cell carcinoma antigen in the detection of cervical cancers.
Lam CP; Yuan CC; Jeng FS; Tsai LC; Yeh SH; Ng HT
Zhonghua Yi Xue Za Zhi (Taipei); 1992 Jul; 50(1):7-13. PubMed ID: 1326391
[TBL] [Abstract][Full Text] [Related]
40. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
